- Home
- GSIW vs ITRM Comparison
GSIW vs ITRM Comparison
Compare GSIW & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSIW | ITRM |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | Hong Kong | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 24.3M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GSIW | ITRM |
|---|---|---|
| Price | $16.75 | $0.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 476.4K | ★ 882.9K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $947.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.14 |
| 52 Week High | $36.90 | $1.42 |
Technical Indicators
Market Signals| Indicator | GSIW | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 59.72 | 40.43 |
| Support Level | $15.28 | $0.14 |
| Resistance Level | $36.90 | $0.39 |
| Average True Range (ATR) | 4.41 | 0.01 |
| MACD | -0.57 | 0.00 |
| Stochastic Oscillator | 22.14 | 65.76 |
Price Performance
Historical ComparisonAbout GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.